Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 7% price increase over the past week, coinciding with the European Commission's regulatory approval of Lynozyfic for relapsed and refractory ...

Regeneron Pharmaceuticals has announced that the European Commission has granted conditional marketing approval for Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory multiple ...

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted conditional marketing approval of Lynozyfic, or linvoseltamab, to treat adults with relapsed ...

Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron ...